According to research published in EMBO Molecular Medicine by teams at Adelaide University and the Olivia Newton-John Cancer Research Institute, a molecular switch driven by low levels of the naturally occurring molecule miR-342 and high activity of the E2F pathway fosters metastatic triple-negative breast cancer. While this aggressive subtype accounts for 10 to 15 percent of Australia’s roughly 21,000 annual breast cancer diagnoses, scientists have now discovered that restoring miR-342 or using existing CDK4/6 inhibitors like palbociclib can dramatically curb tumor spread in pre-clinical models.
Molecular Drivers of Triple-Negative Breast Cancer Metastasis
Triple-negative breast cancer (TNBC) remains notoriously difficult to treat because it lacks the hormone receptors and HER2 proteins that make other forms of the disease vulnerable to targeted therapies, according to Adelaide University Associate Professor Philip Gregory. Most breast cancer deaths stem from metastasis rather than primary tumors. In findings published in EMBO Molecular Medicine, researchers identified that miR-342 acts as a master regulator for genes tied to cancer progression. When miR-342 levels drop, the E2F pathway goes into overdrive. This permits dormant cancer cells that have already traveled through the body to form dangerous secondary tumors in organs like the lungs and bones, as noted by Associate Professor Gregory.
Repurposing CDK4/6 Inhibitors for TNBC Treatment
To combat this metastatic spread, researchers tested the existing breast cancer drug palbociclib, a CDK4/6 inhibitor typically prescribed for advanced hormone receptor-positive breast cancer. According to the study, administering palbociclib successfully suppressed the growth of metastatic tumors in pre-clinical models showing low miR-342 levels. Professor Robin Anderson of the Olivia Newton-John Cancer Research Institute noted that the treatment proved especially effective when given after cancer cells had already spread, preventing microscopic deposits from developing into life-threatening secondary cancers. Measuring miR-342 levels could soon help clinicians pinpoint which TNBC patients will benefit most from this repurposed drug approach.
Did You Know? Triple-negative breast cancer accounts for roughly 10% to 15% of all breast cancer diagnoses in Australia each year, yet it drives a disproportionate share of mortality due to its rapid tendency to spread to distant organs.
Parallel Breakthroughs in Enzyme-Targeting Molecules
In a separate line of inquiry published in Cell Reports Medicine, researchers at Oregon Health & Science University developed an experimental molecule named SU212 to tackle difficult cases of triple-negative breast cancer. According to senior author Sanjay V. Malhotra, co-director of the Center for Experimental Therapeutics in the OHSU Knight Cancer Institute, SU212 attaches to an enzyme called enolase 1 (ENO1). This enzyme regulates cellular glucose levels and is overexpressed in cancer cells. By binding to ENO1, SU212 forces the enzyme to degrade, which suppresses tumor growth and limits metastasis in humanized mouse models. Malhotra noted that this metabolic disruption could eventually benefit patients with other ENO1-influenced cancers, such as glioma, pancreatic cancer, and thyroid carcinoma, as well as those managing metabolic disorders like diabetes.
Next Steps for Pre-Clinical Validation and Clinical Trials
Both research groups are pushing to transition their laboratory breakthroughs into human clinical trials. The Adelaide University and Olivia Newton-John team plan to validate their miR-342 and palbociclib findings using patient-derived pre-clinical models before testing safety and efficacy in people. Meanwhile, according to OHSU’s Malhotra, moving the SU212 molecule toward clinical trials requires substantial funding, regulatory approval from the Food and Drug Administration, and coordinated human testing. These concurrent developments offer renewed hope for personalizing treatments for one of oncology’s most aggressive challenges.
Frequently Asked Questions
-
What is triple-negative breast cancer?
According to researchers, triple-negative breast cancer is an aggressive subtype that lacks hormone receptors and HER2 proteins, rendering traditional hormone-based therapies ineffective. -
How does miR-342 affect cancer spread?
Low levels of miR-342 lead to overactivation of the E2F pathway, which allows dormant cancer cells to develop into secondary tumors in distant organs, according to findings from Adelaide University. -
What is palbociclib used for?
Palbociclib is an existing CDK4/6 inhibitor normally used for advanced hormone receptor-positive breast cancer, but recent pre-clinical studies suggest it can also suppress metastatic growth in TNBC patients with low miR-342 levels. -
What does the SU212 molecule do?
According to Oregon Health & Science University researchers, SU212 targets and degrades the ENO1 enzyme, disrupting glucose metabolism in cancer cells to curb tumor growth and metastasis.
Want to stay informed on the latest breakthroughs in oncology and clinical trials? Subscribe to our newsletter for weekly updates, or leave a comment below to join the discussion.
Keep reading